- Home
- ENZ vs STTK Comparison
ENZ vs STTK Comparison
Compare ENZ & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENZ
- STTK
- Stock Information
- Founded
- ENZ 1976
- STTK 2016
- Country
- ENZ United States
- STTK United States
- Employees
- ENZ N/A
- STTK N/A
- Industry
- ENZ Medical Specialities
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ENZ Health Care
- STTK Health Care
- Exchange
- ENZ Nasdaq
- STTK Nasdaq
- Market Cap
- ENZ 34.2M
- STTK 36.2M
- IPO Year
- ENZ N/A
- STTK 2020
- Fundamental
- Price
- ENZ $0.31
- STTK $0.77
- Analyst Decision
- ENZ
- STTK Hold
- Analyst Count
- ENZ 0
- STTK 4
- Target Price
- ENZ N/A
- STTK $3.00
- AVG Volume (30 Days)
- ENZ 625.0K
- STTK 301.6K
- Earning Date
- ENZ 06-12-2025
- STTK 05-01-2025
- Dividend Yield
- ENZ 31.59%
- STTK N/A
- EPS Growth
- ENZ N/A
- STTK N/A
- EPS
- ENZ N/A
- STTK N/A
- Revenue
- ENZ $29,094,000.00
- STTK $5,721,000.00
- Revenue This Year
- ENZ N/A
- STTK N/A
- Revenue Next Year
- ENZ N/A
- STTK N/A
- P/E Ratio
- ENZ N/A
- STTK N/A
- Revenue Growth
- ENZ N/A
- STTK 245.26
- 52 Week Low
- ENZ $0.25
- STTK $0.69
- 52 Week High
- ENZ $1.27
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- ENZ 39.61
- STTK 40.89
- Support Level
- ENZ $0.26
- STTK $0.85
- Resistance Level
- ENZ $0.42
- STTK $0.95
- Average True Range (ATR)
- ENZ 0.07
- STTK 0.17
- MACD
- ENZ 0.01
- STTK -0.01
- Stochastic Oscillator
- ENZ 35.29
- STTK 10.15
About ENZ Enzo Biochem Inc. ($0.01 Par Value)
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.